Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses
In: Cancer Chemotherapy and Pharmacology, Jg. 86 (2020), Heft 5, S. 693-699
academicJournal
Zugriff:
Purpose Hyperammonemia is an important adverse event associated with 5-fluorouracil (5FU) from 5FU metabolite accumulation. We present a case of an advanced gastric cancer patient with chronic renal failure, who was treated with 5FU/leucovorin (LV) infusion chemotherapy (2-h infusion of LV and 5FU bolus followed by 46-h 5FU continuous infusion on day 1; repeated every 2 weeks) and developed hyperammonemia, with the aim of exploring an appropriate hemodialysis (HD) schedule to resolve its symptoms. Methods The blood concentrations of 5FU and its metabolites, α-fluoro-β-alanine (FBAL), and monofluoroacetate (FA) of a patient who had hyperammonemia from seven courses of palliative 5FU/LV therapy for gastric cancer were measured by liquid chromatography–mass spectrometry. Results On the third day of the first cycle, the patient presented with symptomatic hyperammonemia relieved by emergency HD. Thereafter, the 5FU dose was reduced; however, in cycles 2–4, the patient developed symptomatic hyperammonemia and underwent HD on day 3 for hyperammonemia management. In cycles 5–7, the timing of scheduled HD administration was changed from day 3 to day 2, preventing symptomatic hyperammonemia. The maximum ammonia and 5FU metabolite levels were significantly lower in cycles 5–7 than in cycles 2–4 (NH3 75 ± 38 vs 303 ± 119 μg/dL, FBAL 13.7 ± 2.5 vs 19.7 ± 2.0 μg/mL, FA 204.0 ± 91.6 vs 395.9 ± 12.6 ng/mL, mean ± standard deviation, all p < 0.05). After seven cycles, partial response was confirmed. Conclusion HD on day 2 instead of 3 may prevent hyperammonemia in 5FU/LV therapy.
Titel: |
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses
|
---|---|
Autor/in / Beteiligte Person: | Ozaki, Yoshinao ; Imamaki, Hirotaka ; Ikeda, Aki ; Oura, Mitsuaki ; Nakagawa, Shunsaku ; Funakoshi, Taro ; Kataoka, Shigeki ; Nishikawa, Yoshitaka ; Horimatsu, Takahiro ; Yonezawa, Atsushi ; Matsubara, Takeshi ; Yanagita, Motoko ; Muto, Manabu ; Watanabe, Norihiko ; Department of Gastroenterology, Hirakata Kohsai Hospital ; Japan Society for the Promotion of Science |
Link: | |
Zeitschrift: | Cancer Chemotherapy and Pharmacology, Jg. 86 (2020), Heft 5, S. 693-699 |
Veröffentlichung: | Springer Science and Business Media LLC, 2020 |
Medientyp: | academicJournal |
ISSN: | 0344-5704 |
DOI: | 10.1007/s00280-020-04158-1 |
Schlagwort: |
|
Sonstiges: |
|